Strs Ohio raised its stake in Natus Medical Inc. (NASDAQ:BABY) by 8.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 26,200 shares of the company’s stock after buying an additional 2,000 shares during the period. Strs Ohio’s holdings in Natus Medical were worth $990,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of BABY. BlackRock Institutional Trust Company N.A. raised its stake in Natus Medical by 13.4% in the first quarter. BlackRock Institutional Trust Company N.A. now owns 953,413 shares of the company’s stock valued at $36,640,000 after buying an additional 112,582 shares during the last quarter. Kennedy Capital Management Inc. raised its stake in Natus Medical by 88.4% in the first quarter. Kennedy Capital Management Inc. now owns 202,553 shares of the company’s stock valued at $7,784,000 after buying an additional 95,022 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Natus Medical by 227.5% in the first quarter. JPMorgan Chase & Co. now owns 96,350 shares of the company’s stock valued at $3,703,000 after buying an additional 66,933 shares during the last quarter. Bank of Montreal Can purchased a new stake in Natus Medical during the second quarter valued at $1,919,000. Finally, Anderson Hoagland & Co. purchased a new stake in Natus Medical during the second quarter valued at $1,571,000. 87.94% of the stock is owned by hedge funds and other institutional investors.
Shares of Natus Medical Inc. (NASDAQ:BABY) traded down 0.37% during trading on Friday, reaching $40.65. 184,496 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $41.01 and its 200-day moving average price is $37.02. Natus Medical Inc. has a 52-week low of $29.54 and a 52-week high of $51.05. The stock has a market cap of $1.32 billion, a PE ratio of 35.04 and a beta of 0.78.
Natus Medical (NASDAQ:BABY) last issued its earnings results on Wednesday, July 20th. The company reported $0.39 EPS for the quarter, beating the consensus estimate of $0.36 by $0.03. The company earned $96 million during the quarter, compared to analysts’ expectations of $92.71 million. Natus Medical had a net margin of 10.20% and a return on equity of 13.82%. The business’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period in the previous year, the company earned $0.34 EPS. On average, equities research analysts forecast that Natus Medical Inc. will post $1.55 EPS for the current year.
Several research firms have recently commented on BABY. Zacks Investment Research raised shares of Natus Medical from a “hold” rating to a “buy” rating and set a $44.00 price target on the stock in a research note on Thursday, July 7th. Raymond James Financial Inc. raised shares of Natus Medical from a “market perform” rating to an “outperform” rating and set a $46.00 price target on the stock in a research note on Tuesday, September 13th. Finally, Benchmark Co. began coverage on shares of Natus Medical in a research note on Tuesday, October 4th. They set a “buy” rating and a $55.00 price target on the stock.
In other news, insider James B. Hawkins bought 10,000 shares of the company’s stock in a transaction dated Wednesday, September 28th. The stock was bought at an average cost of $38.48 per share, for a total transaction of $384,800.00. Following the transaction, the insider now owns 459,725 shares of the company’s stock, valued at $17,690,218. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 4.80% of the stock is currently owned by insiders.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Want to see what other hedge funds are holding BABY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natus Medical Inc. (NASDAQ:BABY).
Receive News & Ratings for Natus Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.